In conclusion, CHLZT protects against NAFLD by activating AMPKα, inhibiting ACC activity, down-regulating SREBP2 and HMGR, and up-regulating PPAR-γ. Here, SREBF2 is linked to metabolic dysfunction-associated steatotic liver disease.